DuPont Imprelis Tree Damage Lawsuits Centralized in MDL

All DuPont Imprelis lawsuits filed in federal district courts throughout the United States by consumers who lost trees and property value after using the weed killer, will be consolidated for pretrial proceedings as part of a multidistrict litigation, or MDL, in the U.S. District Court for the Eastern District of Pennsylvania.  

The U.S. Judicial Panel on Multidistrict Litigation issued an order establishing the Imprelis MDL on October 20, which will result in the transfer of more than 40 lawsuits from 17 districts. In addition, as DuPont Imprelis lawyers continue to file new cases in federal courts across the country, they will be transferred to the Eastern District of Pennsylvania for coordinated handling before U.S. District Judge Gene E.K. Pratter.

A petition to centralize the Imprelis litigation was originally filed by three different plaintiffs who disagreed on where the cases should be centralized.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

All of the lawsuits involve similar allegations that the weed killer actually killed otherwise healthy trees on golf courses, parks or other property, leaving unattractive dead husks in its wake and lowering property values and owners’ ability to enjoy their property.

While DuPont promoted Imprellis as a herbicide to target broadleaf weeds, such as dandelion, clover, plantains, wild violet and ground ivy, the company advised consumers in June 2011 not to use Imprellis near Norway spruce and white pines.

Since Memorial Day, Imprelis is suspected of causing the death of thousands of shallow-rooted trees on lawns, golf courses, parks and cemeteries throughout the U.S., including willows, poplars and conifers. Lawsuits over Imprelis allege that tens of thousands of additional trees are likely to be killed as a result of the weedkiller.

In August, the EPA ordered a halt of sales and distribution of Imprelis, saying that the herbicide violated federal regulations by failing to warn on the label about the risk to non-target species, like conifer trees.

Centralization of the DuPont Imprellis tree damage litigation as part of an MDL will allow one judge to rule on all pre-trial motions, preventing duplicative or contradictory rulings. Centralized management is also designed to help avoid duplicative discovery and serve the convenience of the parties, witnesses and the court.

Although the cases will be consolidated during pretrial proceedings, if a DePont Imprelis settlement agreement is not reached, each case may be remanded back to it’s originating federal district court for trial.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.